CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant Disease

Locations

1 United States site

Age

< 40 Years

Phase

Phase 1/Phase 2

Study type

Interventional

Gender

All

Interventions

Biological

Compensation

Unknown

About the study

This study’s goal is to determine the frequency and severity of acute graft versus host
disease, to evaluate incidence of primary and secondary graft rejection, to assess event free
survival and overall survival, to determine the time to neutrophil and platelet engraftment,
to determine the time to immune reconstitution (including normalization of T, B and natural
killer (NK) cell repertoire and Immunoglobulin G production), and to establish the incidence
of infectious complications including bacterial, viral, fungal and atypical mycobacterial and
other infections following CD34+ selection in children, adolescents and young adults
receiving an allogeneic peripheral blood stem cell transplant from a family member or
unrelated adult donor for a non-malignant disease.

participation requirements

– General Eligibility (All Patients)

– Patient must be < or = 40 years of age. Patients with sickle cell anemia must be at least 2 years of age. - Patient or the patient's legally authorized guardian must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign an informed consent in accordance with the institutional policies approved by the U.S. Department of Health and Human Services. - Approval for the use of this treatment protocol by the individual institution's Human Rights Committee must be obtained, in accordance with the institutional assurance policies of the U. S. Department of Health and Human Services. - Human leukocyte antigen (HLA) typing will be performed by high-resolution molecular DNA typing for HLA Class I A, B, and C and HLA Class II DRB1 and DQB1 alleles. - Unrelated donor: An 8/10, 9/10 or 10/10 matched unrelated adult donor (MUD) will be required for study entry. - Related Donor: A 5/10, 6/10, 7/10, 8/10, 9/10 or 10/10 matched (or partially matched) family donor will be required for study entry. - Non-malignant Disorders per protocol. - Hemoglobinopathies per protocol. - Requirement for CD34+ stem cell selection for a second infusion of stem cells following an allogeneic stem cell transplant from a related or unrelated adult donor. - Additional eligibility for patients with non-malignant disorders receiving myeloablative conditioning - Adequate renal function as determined by the institutional normal range. - Adequate liver function per protocol. - Adequate cardiac function defined by radionucleotide angiogram or echocardiogram. - Adequate pulmonary function by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry >94% on room air.

– Additional eligibility for patients with non-malignant disorders receiving reduced
intensity conditioning

– Adequate renal function as determined by the institutional normal range.

– Adequate liver function per protocol.

– Adequate cardiac function per protocol.

– Adequate pulmonary function per protocol.

participation restrictions

– Patients with documented uncontrolled infection at the time of study entry are not
eligible.

– Pregnancy/Breast-Feeding Females who are pregnant or breast feeding at the time of
study entry are not eligible.

— The following additional exclusion criteria for patients with sickle cell anemia
the following exclusion criteria also apply

– Patients with bridging fibrosis or cirrhosis of the liver.

– Uncontrolled bacterial, viral or fungal infection in the past month.

– Seropositivity for HIV.

– Patients who have received prior hematocrit (HCT) within three months of enrollment
for reduced intensity regimen and within six months for myeloablative regimen/reduced
toxicity regimens.

Locations

  • New York, New York, United States, Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University, 10032